Evidence map›Paper›PMID 30740297›Full record

ArticleJournal of bone oncology2019

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial.

Shenglong Li, Peng Chen, Qiankun Yang

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of bone oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Giant cell tumor of bones- An unsolved puzzle.Journal of clinical orthopaedics and trauma
    Article
4 · The record

Corrections and comments

  • Retraction · 2019-04-01Date of Article and/or Notice Unknown · Lack of Approval from Company/Institution · Lack of IRB/IACUC Approval and/or Compliance · · date of retraction unknown, html page overwrite, date estimated from notifications; separate notice published 2/21/20
  • Retracted
5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shenglong LiDepartment of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No 44 of Xiaoheyan Road, Dadong District, Shenyang, Liaoning Province 110042, China.
Peng ChenDepartment of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No 44 of Xiaoheyan Road, Dadong District, Shenyang, Liaoning Province 110042, China.
Qiankun YangDepartment of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No 44 of Xiaoheyan Road, Dadong District, Shenyang, Liaoning Province 110042, China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven.

objectivesTo compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with surgically unsalvageable giant cell tumor of bone.

methodsA total of 250 patients with surgically unsalvageable giant cell tumor of bone were included in this randomized clinical trial. Patients received either subcutaneous denosumab (DB group; 120 mg per 4 weeks plus an additional 120 mg on days 8 and 15;

resultsDenosumab and zoledronic acid had similar tumor responses (

conclusionsDenosumab is a safe but costly alternative to zoledronic acid for treatment of surgically unsalvageable giant cell tumor of bone.

Indexed as

ALT test, Alanine aminotransferase testANOVA, analysis of varianceAntiresorptiveAST test, Aspartate aminotransferase testBone density conservation agentsCONSORT, Consolidated standards of reporting trialsCTCAE, Common Terminology Criteria for Adverse EventsCT, the computed tomographyDenosumabEMA, the European Medicines AgencyEORTC, European organization for research and treatment of cancerGCTB, giant cell tumor of boneGiant cell tumor of boneMRI, magnetic resonance imagingN, sample populationn, sample sizeRANKL, Receptor activator of nuclear factor kappa-Β ligandRECIST, response evaluation criteria in solid tumorsUS FDA, the United States Food and Drug AdministrationZoledronic acid

Identifiers

PMID30740297
PMCPMC6357891
OpenAlexW2914708579

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.